Primaquine Dosing and Management Guidelines
For adults with normal G6PD activity (≥70%), administer primaquine 15 mg base (26.3 mg salt) daily for 14 days for radical cure of P. vivax/ovale malaria, given concurrently with chloroquine or other blood schizontocide. 1
Dosing Regimens
Radical Cure of P. vivax/P. ovale
Standard regimen (FDA-approved):
- 15 mg base daily for 14 days (total dose 3.5 mg/kg) 1
- Administer concurrently with chloroquine phosphate or other blood-stage antimalarial
- Begin primaquine at the same time as blood schizontocide treatment 1
Alternative high-dose regimen (emerging evidence):
- 0.5 mg/kg/day for 7 days (total dose 3.5 mg/kg) 2, 3
- Recent WHO recommendation (2022) supports this shorter course to improve adherence
- 1.0 mg/kg/day for 7 days (total dose 7 mg/kg) provides superior efficacy 4, 3
The evidence strongly favors higher total dose regimens (7 mg/kg) over the traditional 3.5 mg/kg for preventing relapses, though the FDA label currently only approves the 14-day low-dose regimen 1, 3. The 7-day high-dose regimen offers both improved efficacy and better adherence potential 2.
Chemoprophylaxis (Terminal Prophylaxis)
- 15 mg base daily for 14 days after departure from endemic area 5
- Used following chloroquine suppressive therapy in vivax-endemic regions
- Pediatric dose: 0.3 mg/kg/day 5
Gametocytocidal Dose for P. falciparum
- Single dose 0.25 mg/kg (current WHO recommendation for transmission reduction)
- Previously 0.75 mg/kg; reduced dose has lower hemolytic risk 6
Contraindications and Critical Precautions
Absolute Requirements Before Treatment
G6PD testing is mandatory before prescribing primaquine 5, 7, 8, 1
- Use quantitative point-of-care testing to measure G6PD activity percentage 9, 10
- Do NOT use primaquine if G6PD activity <30% 3
- For G6PD activity 30-70% (intermediate deficiency): Consider 14-day regimen at 0.5 mg/kg/day OR weekly dosing (0.75 mg/kg once weekly for 8 weeks) 11, 10
- Life-threatening hemolysis can occur with prolonged use in G6PD deficiency 5
Additional Contraindications
- Pregnancy and breastfeeding 8, 12, 1
- Previous idiosyncratic reaction to primaquine (hemolytic anemia, methemoglobinemia, leukopenia) 1
- Concurrent use with other hemolytic drugs
- Severe anemia at baseline
Special Populations
Asian populations warrant particular caution:
- Higher prevalence of severe G6PD deficiency variants (Mediterranean B- variant) 5, 11
- In populations with severe G6PD deficiency, older guidelines recommended limiting primaquine to ≤5 days, though this is inadequate for radical cure 5
Monitoring Recommendations
Baseline Assessment
- G6PD quantitative testing (≥70% activity required for standard dosing) 11, 9
- Complete blood count with hemoglobin
- Baseline ECG if cardiac disease, long QT syndrome, ventricular arrhythmias, uncorrected electrolytes, or bradycardia <50 bpm 1
During Treatment
Blood monitoring schedule:
- Day 2 or 3: Community-based review for symptoms 10
- Day 7: Hemoglobin check (especially for higher dose regimens)
- Day 14: Complete blood count 1
Discontinue immediately if:
- Marked darkening of urine (hemoglobinuria)
- Sudden decrease in hemoglobin concentration
- Sudden decrease in leukocyte count 1
Clinically significant hemolysis defined as:
- Hemoglobin drop ≥25% to <7 g/dL, OR
- Absolute hemoglobin drop >5 g/dL 3
In G6PD-normal patients (≥30% activity), clinically significant hemolytic events are uncommon even with high-dose regimens 3. Among 1,378 patients in Ethiopian studies, only 1 patient on 0.5 mg/kg daily had ≥25% hemoglobin fall to <7 g/dL 3.
ECG Monitoring
- Required for patients with cardiac disease, QT prolongation risk factors, or concurrent QT-prolonging medications 1
- Primaquine can potentially prolong QT interval
Adverse Effects and Tolerability
Common mild effects:
- Gastrointestinal disturbance (nausea, vomiting): 16-24% on days 5-7 3
- Abdominal discomfort
- Generally transient and self-limited 5, 13
Serious but rare:
Safety data from recent trials:
- No serious adverse events directly attributable to primaquine in large implementation studies 2, 9
- High-dose 7-day regimens well tolerated, including in patients with intermediate G6PD activity 2
- Treatment-limiting adverse events rare; non-serious events mild and transient 13
Key Clinical Pitfalls
Failing to test for G6PD before prescribing: This is the most critical error and can result in life-threatening hemolysis 5, 1
Using inadequate primaquine doses: Five-day regimens have 10-fold higher relapse rates than 14-day regimens 13. Three-day regimens show 3-fold higher relapse 13
Assuming all G6PD deficiency is equally severe: Mediterranean variants (B-) carry very high hemolysis risk, while African variants (A-) have milder deficiency and relative resistance to severe hemolysis 11
Not educating patients about hemolysis warning signs: Patients must know to report dark urine immediately 1
Delaying primaquine start: Begin concurrently with blood schizontocide, not after completion 1
Overdosing in children: Adult dose of 15 mg base should NOT be exceeded; calculate pediatric doses carefully by weight (0.25-0.3 mg/kg/day) 5, 1
Operational Considerations
Healthcare provider compliance with revised algorithms incorporating G6PD testing and high-dose primaquine is achievable:
- 96.6% compliance from provider perspective in Peruvian implementation study 9
- 98.7% correct treatment from patient perspective 9
- Feasible in both urban/periurban and remote/rural settings 9
Storage and dispensing: